Arcturus Therapeutics Holdings Capital Raise of $50M
Arcturus Therapeutics entered into a securities purchase agreement with Meiji Seika Pharma for the sale of 2,466,395 shares of common stock at $20.27 per share, raising $50 million in gross proceeds. The investment was made at an 80% premium to the 30-day average closing price and is part of an expanded collaboration including a license agreement for ARCT-154 technology and a pandemic preparedness MOU in Japan.
- Value
- $50M
- Counterparty
- Meiji Seika Pharma Co., Ltd.
“The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”
Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics